
Opinion|Videos|December 16, 2024
Exploring DMTs: Blood-Brain Barrier Penetration and Cognitive Health Benefits
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Fingolimod, siponimod, and natalizumab can penetrate the blood-brain barrier, potentially impacting brain health directly.
- The impact of DMTs on cognitive health is under investigation, with some evidence suggesting benefits in slowing cognitive decline.
Panelists discuss how disease-modifying therapies (DMTs) like dimethyl fumarate, fingolimod, and cladribine demonstrate potential blood-brain barrier penetration, offering neuroprotective mechanisms. While these therapies show promise in mitigating cognitive decline, their impacts vary, highlighting the complex interplay among neuroinflammation, immune modulation, and cognitive preservation in multiple sclerosis management.
Advertisement
Video content above is prompted by the following:
- Which of the DMTs can penetrate the blood-brain barrier and have the potential to impact brain health directly?
- What is our understanding of the impact of various DMTs on cognitive health?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Current Treatment Strategies for Dravet Syndrome
2
NeurologyLive®'s Conference Coverage, Oveporexton Displays Symptom Improvement in NT1, FDA Allows BLA for AMT-130 in HD
3
FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway
4
Beyond Motor Symptoms: The Power of Connection in Parkinson Disease
5















